These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35917244)
1. FDA-Approved Drugs to Treat Overweight and Obesity. J Psychosoc Nurs Ment Health Serv; 2022 Aug; 60(8):7-8. PubMed ID: 35917244 [No Abstract] [Full Text] [Related]
2. FDA-Approved Drugs to Treat Overweight and Obesity. J Psychosoc Nurs Ment Health Serv; 2021 Aug; 59(8):5-6. PubMed ID: 34343052 [No Abstract] [Full Text] [Related]
3. Drug management of obesity--efficacy versus safety. Astrup A N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205 [No Abstract] [Full Text] [Related]
4. Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. Aggarwal R; Vaduganathan M; Chiu N; Bhatt DL Prog Cardiovasc Dis; 2021; 68():97-98. PubMed ID: 34560122 [No Abstract] [Full Text] [Related]
5. Comparison table: some FDA-approved drugs for weight management. Med Lett Drugs Ther; 2018 Jun; 60(1548):e98-e100. PubMed ID: 29913464 [No Abstract] [Full Text] [Related]
10. [The pharmacotherapy of obesity]. Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782 [TBL] [Abstract][Full Text] [Related]
11. Anti-obesity drugs: to be or not to be? Dvorak RV; Sharma AM; Astrup A Obes Rev; 2010 Dec; 11(12):833-4. PubMed ID: 21054758 [No Abstract] [Full Text] [Related]
12. FDA approves first canine diet drug. Nolen RS J Am Vet Med Assoc; 2007 Mar; 230(5):641-2. PubMed ID: 17380625 [No Abstract] [Full Text] [Related]
13. Molecule of the month. The 'skinny' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval. Lindsley CW Curr Top Med Chem; 2008; 8(17):1553. PubMed ID: 19097323 [No Abstract] [Full Text] [Related]
14. FDA approves Belviq to treat some overweight or obese adults. Home Healthc Nurse; 2012 Sep; 30(8):443-4. PubMed ID: 23097775 [No Abstract] [Full Text] [Related]
15. Guidelines for approval of anti-obesity drugs affecting atherosclerosis and/or lipids. The international union of pharmacology (IUPHAR). Anderson JW Am J Cardiol; 1998 Apr; 81(8A):29F-30F. PubMed ID: 9604902 [No Abstract] [Full Text] [Related]
16. Lorcaserin for weight loss: insights into US Food and Drug Administration approval. Miller LE J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720 [No Abstract] [Full Text] [Related]
17. Update on pharmacology of obesity: benefits and risks. Cabrerizo García L; Ramos-Leví A; Moreno Lopera C; Rubio Herrera MA Nutr Hosp; 2013 Sep; 28 Suppl 5():121-7. PubMed ID: 24010752 [TBL] [Abstract][Full Text] [Related]
18. Companies throw their weight behind new antiobesity drugs. Cahoon L Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442 [No Abstract] [Full Text] [Related]
19. Drugs to Treat Overweight and Obesity. J Psychosoc Nurs Ment Health Serv; 2020 Aug; 58(8):9-10. PubMed ID: 32744641 [No Abstract] [Full Text] [Related]
20. FDA-Approved Anti-Obesity Drugs in the United States. Daneschvar HL; Aronson MD; Smetana GW Am J Med; 2016 Aug; 129(8):879.e1-6. PubMed ID: 26949003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]